Endodontic Medications for Irreversible Pulpitis: Articaine or Eugenol?

Endodontic Inflammation Clinical Trial

Official title:

Articaine or Eugenol: a Study on the Choice of Endodontic Medication in the Emergency Management of Irreversible Pulpitis of a Mature Permanent Tooth

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03472456
• Other study ID #: 6953
• Status: Completed
• Start date: March 22, 2018
• Est. completion date: October 24, 2019

Study information

• Verified date: September 2020
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of the study is to determine which of the two commonly used endodontic medications (Eugenol VS Articaine) is most effective in controlling postoperative pain in irreversible pulpitis of the mature permanent tooth in adults. To do so, an assessment of the pain felt by patients will be carried out a few days apart. The supposed results are that the medications are equivalent in terms of effectiveness on the pain, but could then present different economic arguments

Description:

In irreversible pulpitis of the mature permanent tooth, the enrolled patients receive endodontic medications (Eugenol or Articaine) in order to determine which one is the more efficient to control the pain.

These patients would have received the same medication without this study. That's why this is an obsevationnal study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: October 24, 2019
• Est. primary completion date: March 22, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patient, major, affiliated to a social health insurance scheme

• Patient having agreed to participate in the study

• Urgent consultant patient for irreversible pulpitis

• Patient understanding French

Exclusion Criteria:

• Refusal of the patient to participate in the study

• Impossibility of performing the surgical procedure

• Impossibility to give the subject information enlightened (difficulty of understanding ...)

• Subject under the protection of justice, or under guardianship

• General contraindication to endodontic treatment in 2 sessions (high risk of infectious endocarditis, for example)

• Chronic intake of analgesic drugs

Related Conditions & MeSH terms

• Endodontic Inflammation
• Inflammation
• Operative Dentistry
• Pulpitides
• Pulpitis
• Toothache
• Toothaches

Intervention

Drug:
• Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
• Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol

Locations

Country	Name	City	State
France	Les Hôpitaux Universitaires de Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain evolution (decrease or increase the intensity of the pain)	Evolution of pain (using a score of 0 to 10)	7 days